MGTA News and Press, Magenta Therapeutics Inc. From 11/13/19

–Early clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of cells in 11 of 12 healthy volunteers; updated data to be presented at ASH–  –Reported first-ever successful gene therapy transplant of non-human primates with ...

-- Single dose of CD45-ADC shown to remove disease-causing cells and halt disease in models of multiple sclerosis, systemic sclerosis and inflammatory arthritis -- -- Magenta exercises option with Heidelberg Pharma for antibody-drug conjugates using an amanitin payload and targeting CD...

-- First clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of stem cells in 11 of 12 healthy volunteers within hours; updated data including apheresis collection to be presented at ASH – -- Single dose of CD117-ADC demonstrates first-ever...

Investment thesis: Biotechnology investors work on the assumption that news surrounding assets in clinical development impact company valuation significantly. Our analysis suggests that focusing on earlier events, such as Phase 2 and 3 data release, represents a stronger short-term, cataly...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the appointment of Jan Pinkas, Ph.D., as Senior Vice President, Translational Sciences. The Company ...

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had another lackluster week, opening last Tuesday (September 3) after the long weekend at 3,219.88 points before settling at 3,229.42 points as of 1:32 p.m. EDT on Friday (September 6). Over the short trading week, the US Food and Drug Admin...

Magenta Therapeutics (NASDAQ: MGTA ) received a boost on Wednesday (September 4) from the US Food and Drug Administration (FDA) for its cell therapy, MGTA-456. In a press release , the company said that the regulatory agency has given its therapy a Regenerative Medicine Advance Therapy...

The FDA designates Magenta Therapeutics' ( MGTA +1.3% ) one-time cell therapy MGTA-456 a Regenerative Medicine Advance Therapy (RMAT) for the treatment of multiple inherited metabolic disorders. More news on: Magenta Therapeutics, Inc., Healthcare stocks news, Read more ...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advance Therapy (RMAT...

Note: The following article assumes you are familiar with my introductory article on Magenta. Introduction Magenta Therapeutics ( MGTA ) first came on my radar in June of last year before it began trading on Nasdaq. I was interested by their broad, practice-changing portfolio an...